Xiao Yu-Xuan, Chen Jun, Li Zhuo-Ying, Zou Yi-Xin, Zhou Xiao-Hui, Zhang Wei, Li Hong-Lan, Bischof Evelyne Y, Xiang Yong-Bing
Department of Epidemiology & State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200032, China.
School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Heliyon. 2025 Feb 20;11(4):e42853. doi: 10.1016/j.heliyon.2025.e42853. eCollection 2025 Feb 28.
Gallbladder cancer has historically been characterized with a poor prognosis. This study aims to describe the global patterns and temporal trends in gallbladder cancer survival using data from cancer registries.
We conducted a systematic review by searching six databases-PubMed, Web of Science, EMBASE, SEER, CNKI, and Wanfang-for using of registry-based data published before January 1, 2024. Survival data were carefully extracted and analyzed from the final set of included studies.
Among the 55 studies included, more than 320,000 people, suggest that survival improvements for gallbladder cancer have stagnated over the past three decades. No significant improvements in 5-year relative survival rates were observed worldwide. After age standardization, the highest 5-year relative survival rate is 30.6 % (Changzhou, China, 2011-2013 and Korea, 2013-2019), while the lowest is 6.0 % (Austria, 1990). The 5-year relative survival rate for gallbladder cancer was generally higher in Asian populations than in other regions. Survival rates were more favorable in younger individuals, with no differences in survival observed between the sexes.
Over the past 30 years, the prognosis of patients with gallbladder cancer has not improved significantly worldwide. There is an urgent need for new treatments for gallbladder cancer as well as simple and effective screening methods to improve the survival rate of gallbladder cancer.
胆囊癌历来预后较差。本研究旨在利用癌症登记处的数据描述胆囊癌生存的全球模式和时间趋势。
我们通过检索六个数据库——PubMed、科学网、EMBASE、监测、中国知网和万方——对2024年1月1日前发表的基于登记处的数据进行了系统评价。从纳入研究的最终集中仔细提取并分析了生存数据。
在纳入的55项研究中,超过32万人的数据表明,在过去三十年中,胆囊癌的生存改善停滞不前。全球范围内未观察到5年相对生存率有显著改善。年龄标准化后,最高的5年相对生存率为30.6%(中国常州,2011 - 2013年以及韩国,2013 - 2019年),而最低的为6.0%(奥地利,1990年)。胆囊癌的5年相对生存率在亚洲人群中总体高于其他地区。年轻个体的生存率更优,男女之间未观察到生存差异。
在过去30年中,全球范围内胆囊癌患者的预后没有显著改善。迫切需要新的胆囊癌治疗方法以及简单有效的筛查方法来提高胆囊癌的生存率。